Business Segments · Research and development expense
BioPharma Systems — Research and development expense
Becton, Dickinson and Company BioPharma Systems — Research and development expense decreased by 5.6% to $17M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ2 2026May 7, 2026
Rolls up toR&D
How to read this metric
An increase reflects a commitment to innovation and future product development, though it impacts short-term profitability.
Detailed definition
This metric tracks the total investment in research and development activities specifically dedicated to the BioPharma S...
Peer comparison
Standard R&D expenditure metric for segments focused on product innovation in the life sciences sector.
Metric ID:
bdx_segment_biopharma_systems_research_and_development_expenseHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|
| Value | $17M | $18M | $18M | $17M |
| QoQ Change | — | +5.9% | +0.0% | -5.6% |
| YoY Change | — | — | +5.9% | -5.6% |
Range$17M – $18M
Avg YoY Growth+0.2%
Median YoY Growth+0.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — research and development expense?
- Becton, Dickinson and Company (BDX) reported biopharma systems — research and development expense of $17M in Q1 2026.
- What does biopharma systems — research and development expense mean?
- Total spending on R&D activities within the BioPharma Systems segment.